Complete pathologic response after neoadjuvant treatment with vemurafenib for malignant melanoma.
Division of Oncology, Rambam Health Care Campus and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Orit
O
Kaidar-Person
Department of Radiology, Rambam Health Care Campus and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Ayelet
A
Eran
Division of Oncology, Rambam Health Care Campus and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. Electronic address: g_barsela@rambam.health.gov.il.
Gil
G
Bar-Sela
D000284:Administration, Oral; D000328:Adult; D001707:Biopsy, Needle; D062109:Dermatologic Surgical Procedures / Q000379:methods; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000000981:diagnostic imaging / Q000473:pathology* / Q000628:therapy*; D020360:Neoadjuvant Therapy / Q000379:methods*; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods; D021701:Sentinel Lymph Node Biopsy; D012878:Skin Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology* / Q000628:therapy*; D013449:Sulfonamides / Q000627:therapeutic use*; D016896:Treatment Outcome; D000077484:Vemurafenib
D007211:Indoles; D013449:Sulfonamides; D019788:Fluorodeoxyglucose F18; D000077484:Vemurafenib